SGLT2 inhibitor
Also written as: SGLT2 — Sodium-glucose co-transporter 2
Antidiabetic medication that blocks glucose reabsorption in the kidney.
Full Definition
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of antidiabetic medications that work by blocking glucose reabsorption in the proximal tubule of the kidney, leading to increased urinary glucose excretion and reduced blood glucose levels. Beyond glycemic benefits, SGLT2 inhibitors have demonstrated remarkable cardio-renal protective effects, reducing hospitalizations for heart failure and slowing progression of chronic kidney disease. These agents work independently of insulin secretion and carry a low risk of hypoglycemia when used as monotherapy.
Usage
Usage note: SGLT2 may be written with or without hyphen (SGLT-2), but be consistent within documents.
In Context
- "SGLT2 inhibitor therapy reduced heart failure hospitalizations by 35% regardless of diabetes status." — Cardiovascular outcome trial
- "Genital mycotic infections are the most common adverse effect of SGLT2 inhibitors." — Safety profile analysis